Treatments for nervous disorders

Abstract

This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.

1 . A method of treating or enhancing the treatment of a disorder selected from: 
 a) Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and    b) Attention Deficit Hyperactivity Disorder (ADHD);    comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.    
     
     
         2 . The method of  claim 1  where Reboxetine is used to treat or enhance the treatment of Tobacco and or Nicotine Addiction.  
     
     
         3 . The method of  claim 2  where Reboxetine is used to reduce the craving for Tobacco or Nicotine containing products.  
     
     
         4 . The method of  claim 2  where Reboxetine is used to reduce the smoking or chewing of Tobacco or Nicotine containing products.  
     
     
         5 . The method of  claim 1  where Reboxetine is used to treat or enhance the treatment of Attention Deficit Hyperactivity Disorder (ADHD).  
     
     
         6 . The method of  claim 5  where Reboxetine is used to increase the attention span and calm individuals afflicted with ADHD.  
     
     
         7 . A method for treating or enhancing the treatment of a disorder selected from: 
 a) Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and p 1  b) Attention Deficit Hyperactivity Disorder (ADHD);    comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient in need of an effective treatment thereof.    
     
     
         8 . The use of Reboxetine or its pharmaceutically acceptable salts in the manufacture of a medicament to treat: 
 a) Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and    b) Attention Deficit Hyperactivity Disorder (ADHD);    and for any of the symptoms of any of those diseases.    
     
     
         9 . The method or use in claims  1 - 8  where the reboxetine dose range is 4 to 10 mg. per patient per day.  
     
     
         10 . The method or use in claims  1 - 8  where the reboxetine dose range is 6 to 8 mg. per patient per day.